Skip to main content

Advertisement

SpringerLink
Log in

Treatment endpoints for advanced cholangiocarcinoma

  • Viewpoint
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gores GJ (2003) Cholangiocarcinoma: current concepts and insights. Hepatology 37: 961–969

    Article  Google Scholar 

  2. Shaib Y and El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115–125

    Article  Google Scholar 

  3. Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216

    Article  CAS  Google Scholar 

  4. Millar AW and Lynch KP (2003) Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer 3: 540–545

    Article  CAS  Google Scholar 

  5. Levy I and Sherman M (2002) Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50: 881–885

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reuben R Eisenberg Professor of Medicine Mayo Clinic College of Medicine, Rochester, MN, USA

    Gregory J Gores

  2. Instructor of Surgery Mayo Clinic College of Medicine, Rochester, MN, USA

    Edwina S Baskin-Bey

  3. Professor of Medicine Mayo Clinic College of Medicine, Rochester, MN, USA

    Todd H Baron

  4. Associate Professor of Oncology, all at Mayo Clinic College of Medicine, Rochester, MN, USA

    Steven R Alberts

Authors
  1. Gregory J Gores
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edwina S Baskin-Bey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Todd H Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven R Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory J Gores.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figure 1

Disease progression in the left lobe of a patient with cholangiocarcinoma. Top panel: Representative endoscopic retrograde cholangiograms of a patient with advanced hilar cholangiocarcinoma. Lower panel: Quantitation of brightness area product (BAP) for the cholangiograms shown in the top panel. The BAP, a quantitative measurement of the area represented by contrast-filled bile ducts, mathematically represents the average brightness of pixels or voxels above a threshold value in a region of interest. For each cholangiogram, the biliary region of choice is mapped (areas shaded in red) and the number of pixels or voxels are measured which correspond to a brightness threshold value. The marked decrease in BAP for the cholangiogram dated 10 September 2003 compared with the one dated 5 June 2003 should be noted. This loss in biliary surface area, depicting disease progression, was apparent even when biochemical studies had improved due to better stenting of the right lobe. On 5 June 2003, total serum bilirubin was 13.2 mg/dl and serum alkaline phosphatase was 870 U/L (normal <115 U/L). On 10 September 2003, total serum bilirubin was 5.2 mg/dl and serum alkaline phosphatase was 646 U/L.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gores, G., Baskin-Bey, E., Baron, T. et al. Treatment endpoints for advanced cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 1, 4–5 (2004). https://doi.org/10.1038/ncpgasthep0008

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0008

  • Springer Nature Limited

This article is cited by

Search

Navigation